22:57:52 EST Sat 04 Dec 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Opsens Inc
Symbol OPS
Shares Issued 106,639,914
Close 2021-04-21 C$ 1.80
Recent Sedar Documents

Opsens signs agreement for Cathmedical systems

2021-04-21 09:10 ET - News Release

Mr. Louis Laflamme reports

OPSENS INTEGRATES ITS OPTOWIRE'S DPR AND FFR ALGORITHMS WITHIN CATHMEDICAL CARDIOVASCULAR'S PICASSO SYSTEM IN SPAIN

Opsens Inc. has signed an agreement with Cathmedical Cardiovascular SA for the integration of its coronary physiology algorithms into the Picasso system, a next-generation hemodynamic system. The integrated systems will initially focus on the Spanish cardiology market where the Picasso has a dominant market share.

This partnership agreement allows interventional cardiologists using this system to benefit from full integration into the catheterization laboratory and to offer superior diagnosis and treatment to their patients. Combined with the OptoWire III, the full power of coronary physiology indices such as the Opsens's diastolic pressure ratio (or dPR) is now available within the Picasso system for optimal integration into the work flow.

Louis Laflamme, president and chief executive officer of Opsens, commented: "We are excited to bring to the cardiac physicians in Spain, a seamless integration of Opsens's dPR technology with Cathmedical's next-generation hemodynamic system. Cardiologists have already had the opportunity to appreciate independently the Picasso system and the OptoWire III for their performances, ease of use and accurate measurements. We believe their integration brings together the best of both worlds -- hemodynamic systems and physiology guide wires -- merging functionalities that will improve physician work flow, ease their decision-making process, and may lead to better patient outcomes. This partnership is an example of the value Opsens can offer by combining its expertise with the one of its partners."

Alfredo Garcia, general manager of Cathmedical, said: "We are very pleased with this partnership with Opsens. It provides our customers access to the combination of the best hemodynamic system to the best pressure guide wire system on the market."

"Integrating the OptoWire III into the cathlab system is quick and easy, freeing up space on the operating table with the removal of equipment. Within moments, the cardiologist is able to connect the OptoWire III and perform the procedure on his patient," said Dr. Carlos Moreno, interventional cardiologist at Getafe University Hospital (Madrid).

The Opsens OptoWire III is a modern pressure guide wire designed for clinical practice to diagnose, treat and confirm results in coronary arteries. The unmatched precision of its second-generation fibre optic sensor, Fidela, translates into the lowest drift in the industry and represents an exclusive feature, for which Opsens stands out in the market. The value of Fidela precision is supported by peer-reviewed literature showing that the accuracy of the pressure measurement is even more crucial when physiology guide wires are used for indices without hyperemia.

Coronary artery disease is the blockage or narrowing (stenosis) of the arteries that supply blood to the heart muscle, often due to the buildup of fatty plaque inside the arteries, which may cause heart attacks. Several studies, such as the FAME study, showed that when fractional flow reserve is used prior to percutaneous coronary intervention, patients' outcomes are improved with major adverse cardiac events significantly reduced.

About Opsens Inc.

Opsens focuses mainly on coronary physiology products in interventional cardiology. Opsens offers an advanced optical-based pressure guide wire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fibre optic pressure guide wire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 100,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan and Canada.

Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing solutions for critical applications.

© 2021 Canjex Publishing Ltd. All rights reserved.